Association between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis
Association between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis
复制标题
大血管巨细胞动脉炎患者大血管病变模式与治疗结果之间的关联
DOI:
10.1093/mr/roac122
复制
发表时间:
2022
影响因子:
2.2
通讯作者:
Komagata Yoshi
中科院分区:
文献类型:
--
作者:
Sugihara Takahiko;Uchida Haruhito A;Yoshifuji Hajime;Maejima Yasuhiro;Naniwa Taio;Katsumata Yasuhiro;Okazaki Takahiro;Ishizaki Jun;Murakawa Yohko;Ogawa Noriyoshi;Dobashi Hiroaki;Horita Tetsuya;Tanaka Yoshiya;Furuta Shunsuke;Takeuchi Tsutomu;Komagata Yoshi
ObjectivesWe aimed to identify associations between patterns of large-vessel lesions of large-vessel giant cell arteritis (LV-GCA) and treatment outcomes.MethodsWe extracted data on 68 newly diagnosed patients with LV-GCA from a retrospective, multi-centric, nationwide registry of GCA patients treated with glucocorticoids between 2007 and 2014. Patients with aortic lesions were identified based on the findings from contrast-enhanced computed tomography, magnetic resonance imaging, or positron emission tomography–computed tomography (Group 2,n= 49). Patients without aortic lesions were subdivided into LV-GCA with or without subclavian lesions defined as Group 1 (n= 9) or Group 3 (n= 10), respectively. The primary outcome evaluation was failure to achieve clinical remission by Week 24 and/or relapse within 104 weeks.ResultsThe mean age and proportion of patients with cranial lesions and polymyalgia rheumatica in Group 2 were numerically lower than in the other two groups. Large-vessel lesions in Group 3 included carotid, pulmonary, renal, hepatic, or mesenteric lesions. The cumulative rate of poor treatment outcomes >2 years was 11.1%, 55.3%, and 88.0% in Groups 1, 2, and 3, respectively (by Kaplan–Meier analysis). The mean time to poor outcome was significantly different between the groups.ConclusionsClassification by subclavian and aortic lesions may be useful to determine treatment strategy.